Naperville, IL -- (SBWire) -- 09/17/2014 --Reportstack, provider of premium market research reports announces the addition of EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2023 market report to its offering
EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2023
Summary"
Age-related macular degeneration (AMD) is a progressive eye condition caused by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly in the developed countries. In addition to the high prevalence of the condition, AMD is associated with severe disability and has a major impact on the quality of life and emotional well-being of an affected individual. AMD is classified into two stages: early AMD and late AMD. Late AMD is the advanced stage of AMD, which is further subclassified as dry AMD (geographic atrophy) and wet AMD (neovascular).
The publisher epidemiologists forecast that the total prevalent cases of AMD in the 7MM will increase from 55,770,401 cases in 2013 to 66,069,370 cases in 2023, at a growth rate of 18.5% over the forecast period. Throughout the forecast period, the US will have the highest number of total prevalent cases of AMD, followed by Japan.
Epidemiological analysis is supported by the use of total prevalence data from epidemiological studies published in peer-reviewed journals. The publisher epidemiologists used uniform methodology across the markets to forecast the total prevalent cases of AMD. The publisher epidemiologists segmented AMD by stages (early AMD and late AMD, and the late AMD subtypes: dry AMD and wet AMD), which allows for a meaningful comparison of the disease populations between markets.
Scope:
- The Age-related Macular Degeneration (AMD) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of AMD segmented by sex and age (50-59 years, 60-69 years, 70-79 years, and =80 years) in these markets. Additionally, The publisher epidemiologists provide the total prevalent cases of AMD segmented by AMD stages: early AMD and late AMD, as well as the late AMD subtypes: dry AMD and wet AMD.
- The AMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.'
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy:
- Develop business strategies by understanding the trends shaping and driving the global AMD market.
- Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for AMD therapeutics in each of the markets covered.
To view the table of contents for this market research report please visit
http://www.reportstack.com/product/171567/epicast-report-age-related-macular-degeneration-epidemiology-forecast-to-2023.html
Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2023